Company News
Organogenesis Shares Jump 20% on Trial Success
Organogenesis Holdings' stock rose about 20% after its PuraPly AM met primary endpoint in a 170‑patient diabetic foot ulcer trial.
The prospective, multi‑center study showed statistically significant
